0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ICOS

ICOS

ICOS Molecule Information

Name:Inducible T-cell costimulator
Target Synonym:CD278;ICOS;Activation-inducible lymphocyte immunomediatory molecule;AILIM
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase ?

ICOS Protein Product ListCompare or Buy

ICOS Molecule Synonym Name

ICOS,CD278,AILIM,Inducible T-cell costimulator

ICOS Molecule Background

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS References

ICOS Related Molecule

ICOS Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
XmAb-23104 (Xencor) Phase Ⅰ Xencor Solid tumours Details
GSK-3359609 GSK-3359609 Phase Ⅱ GlaxoSmithKline Non small cell lung cancer (NSCLC), Solid tumours Details
MEDI-570 (Japan Tobacco) Phase Ⅰ Japan Tobacco, MedImmune Systemic lupus erythematosus Details
Anti-ICOS (Bristol Myers Squibb) BMS-986226 Phase Ⅰ Bristol-Myers Squibb Cancer Details
KY-1044 KY-1044 Phase Ⅱ Kymab Gastric cancer, Non small cell lung cancer (NSCLC), Esophagus cancer, Breast cancer, Liver cancer, Squamous cell cancer, Renal carcinoma, Head and neck cancer, Cervical carcinoma, Pancreatic cancer, Melanoma Details
Vopratelimab JTX-2011 Phase Ⅱ Jounce Therapeutics, Celgene Non small cell lung cancer (NSCLC), Urothelial cancer, Solid tumours Details

This web search service is supported by Google Inc.

totop